Ovagen HomeCompanyInvestorsContact
  Investor relations  
Ovagen   Ovagen
Ovagen Ovagen Ovagen Ovagen  


Ovagen Group Limited is a privately owned company incorporated in the Republic of Ireland. 

Ovagen International Limited (Patent holding company) is a wholly owned subsidiary of Ovagen Group Limited.





2000 – 2002: Concept defined, independent market research and initial BES investment rounds of €1.4M. 

2003 – 2004: Ongoing R & D. 

2004-2008: Perfecting the surgical procedure with the technical expertise of a world expert in germ free technology and a very experienced surgical team. Design of bespoke germ free isolators. Validation of test methods for microbiology screening. 

2007-2008: Extensive market research with large multinational pharmaceutical companies confirms value proposition and market size. Acquired a seven-acre site for new avian facility, detailed design and planning application for Phase 1 building. Funding round of €8M completed. 

2009: Achievement of proof of concept of germ free eggs. Independent verification of Germ Free status by International organisations.

2009 – 2013: Production of germ free eggs from three generations of germ free birds. Global patent protection received. Phase 1 planning application approved and 2,560 sqm state-of-the-art avian facility completed. Total funding raised to date increases to €12M. Awarded EU Framework 7 funding for work on isolation of bone marrow stem cells. 

2014 – 2018: Funding to date increased to €13.8M. Detailed design of two additional manufacturing facilities and a logistics building completed. Planning application granted for all commercial production facilities. Validation of work and design of bespoke avian production isolators to initiate development of initial germ free flock and pilot scale germ free egg production. Pipeline of customer enquiries demonstrating strong market pull and urgent need for our germ free product. H2020 SME Instrument Phase 2 funding application sought. Establishment of transgenic laboratory. Establishment of first transgenic chicken line expressing recombinant antibody for purification of stem cells. 

2019: H2020 SME Inst. Phase 2 funding of €2.356,812 secured to allow pilot scale production of germ free eggs for customer evaluation Q3 2021. 

2020: Intensive capital development programme initiated, senior project director appointed and employee numbers increased. Funding round of €1.18M completed bringing total investment in the project to €17.33M

Total Funding



Facilities (2500msq)

    First generation germ-free flocks

    • Avian Isolators, Incubators
    • Laboratories (Microbiology and Transgenic)
    • R&D
    • Head Office

    Lower Floor Provides:

    • SPF flocks
    • Large Germ-Free (GF) production isolators
    • GF suite for flock of 1000 birds
    • GF feed handling
    • GF egg collection & packaging

    Upper Floor Provides:

    • SPF showers
    • Incubating/Hatching Isolators
    • Transport Isolators
    • Laboratories & QA
    • Head Offices
    • Site BMS & IT facilities

Ovagen Ovagen Ovagen Ovagen Ovagen
Ovagen   Ovagen
Ovagen Ovagen